Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline

A randomized controlled trial

Bliss Kaneshiro, Alison Edelman, Nichole Carlson, Kristin Morgan, Mark Nichols, Jeffrey Jensen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To estimate whether doxycycline, a matrix metalloproteinase inhibitor, would decrease unscheduled bleeding associated with initiation of a continuous oral contraceptive pill. Methods: Participants initiating a continuous oral contraceptive pill (20 micrograms of ethinyl estradiol/90 micrograms of levonorgestrel) were randomly assigned to receive either doxycycline (100 mg orally twice daily) or placebo taken for 5 days at the onset of each bleeding or spotting episode during the first 84 days of the study period. For the final 28 days of the study, participants were observed on the oral contraceptive pill alone. The primary outcome was the number of bleeding and spotting days. A sample size of 66 (33 in each arm) was calculated to detect a 50% reduction in bleeding (β=0.80, α=0.05) and accounted for a 30% dropout rate. Results: Sixty-six women were randomly assinged (33 in each study group). There were no significant differences during the 84-day treatment in bleeding or spotting days (doxycycline [mean {standard error}, placebo, P=.32) or the length of the longest bleeding or spotting episode (doxycycline, placebo, P=.70) between study groups. Similarly, no significant differences in bleeding patterns existed between groups during the final 28 days. Conclusion: Doxycycline, administered once bleeding has started, does not decrease unscheduled bleeding or shorten episodes of unscheduled bleeding in continuous oral contraceptive pill users.

Original languageEnglish (US)
Pages (from-to)1141-1149
Number of pages9
JournalObstetrics and Gynecology
Volume115
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Doxycycline
Oral Contraceptives
Randomized Controlled Trials
Hemorrhage
Metrorrhagia
Therapeutics
Placebos
Levonorgestrel
Ethinyl Estradiol
Matrix Metalloproteinase Inhibitors
Sample Size

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline : A randomized controlled trial. / Kaneshiro, Bliss; Edelman, Alison; Carlson, Nichole; Morgan, Kristin; Nichols, Mark; Jensen, Jeffrey.

In: Obstetrics and Gynecology, Vol. 115, No. 6, 06.2010, p. 1141-1149.

Research output: Contribution to journalArticle

@article{b4808879f20c400781df29f245c9bc58,
title = "Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: A randomized controlled trial",
abstract = "Objective: To estimate whether doxycycline, a matrix metalloproteinase inhibitor, would decrease unscheduled bleeding associated with initiation of a continuous oral contraceptive pill. Methods: Participants initiating a continuous oral contraceptive pill (20 micrograms of ethinyl estradiol/90 micrograms of levonorgestrel) were randomly assigned to receive either doxycycline (100 mg orally twice daily) or placebo taken for 5 days at the onset of each bleeding or spotting episode during the first 84 days of the study period. For the final 28 days of the study, participants were observed on the oral contraceptive pill alone. The primary outcome was the number of bleeding and spotting days. A sample size of 66 (33 in each arm) was calculated to detect a 50{\%} reduction in bleeding (β=0.80, α=0.05) and accounted for a 30{\%} dropout rate. Results: Sixty-six women were randomly assinged (33 in each study group). There were no significant differences during the 84-day treatment in bleeding or spotting days (doxycycline [mean {standard error}, placebo, P=.32) or the length of the longest bleeding or spotting episode (doxycycline, placebo, P=.70) between study groups. Similarly, no significant differences in bleeding patterns existed between groups during the final 28 days. Conclusion: Doxycycline, administered once bleeding has started, does not decrease unscheduled bleeding or shorten episodes of unscheduled bleeding in continuous oral contraceptive pill users.",
author = "Bliss Kaneshiro and Alison Edelman and Nichole Carlson and Kristin Morgan and Mark Nichols and Jeffrey Jensen",
year = "2010",
month = "6",
doi = "10.1097/AOG.0b013e3181e0119c",
language = "English (US)",
volume = "115",
pages = "1141--1149",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline

T2 - A randomized controlled trial

AU - Kaneshiro, Bliss

AU - Edelman, Alison

AU - Carlson, Nichole

AU - Morgan, Kristin

AU - Nichols, Mark

AU - Jensen, Jeffrey

PY - 2010/6

Y1 - 2010/6

N2 - Objective: To estimate whether doxycycline, a matrix metalloproteinase inhibitor, would decrease unscheduled bleeding associated with initiation of a continuous oral contraceptive pill. Methods: Participants initiating a continuous oral contraceptive pill (20 micrograms of ethinyl estradiol/90 micrograms of levonorgestrel) were randomly assigned to receive either doxycycline (100 mg orally twice daily) or placebo taken for 5 days at the onset of each bleeding or spotting episode during the first 84 days of the study period. For the final 28 days of the study, participants were observed on the oral contraceptive pill alone. The primary outcome was the number of bleeding and spotting days. A sample size of 66 (33 in each arm) was calculated to detect a 50% reduction in bleeding (β=0.80, α=0.05) and accounted for a 30% dropout rate. Results: Sixty-six women were randomly assinged (33 in each study group). There were no significant differences during the 84-day treatment in bleeding or spotting days (doxycycline [mean {standard error}, placebo, P=.32) or the length of the longest bleeding or spotting episode (doxycycline, placebo, P=.70) between study groups. Similarly, no significant differences in bleeding patterns existed between groups during the final 28 days. Conclusion: Doxycycline, administered once bleeding has started, does not decrease unscheduled bleeding or shorten episodes of unscheduled bleeding in continuous oral contraceptive pill users.

AB - Objective: To estimate whether doxycycline, a matrix metalloproteinase inhibitor, would decrease unscheduled bleeding associated with initiation of a continuous oral contraceptive pill. Methods: Participants initiating a continuous oral contraceptive pill (20 micrograms of ethinyl estradiol/90 micrograms of levonorgestrel) were randomly assigned to receive either doxycycline (100 mg orally twice daily) or placebo taken for 5 days at the onset of each bleeding or spotting episode during the first 84 days of the study period. For the final 28 days of the study, participants were observed on the oral contraceptive pill alone. The primary outcome was the number of bleeding and spotting days. A sample size of 66 (33 in each arm) was calculated to detect a 50% reduction in bleeding (β=0.80, α=0.05) and accounted for a 30% dropout rate. Results: Sixty-six women were randomly assinged (33 in each study group). There were no significant differences during the 84-day treatment in bleeding or spotting days (doxycycline [mean {standard error}, placebo, P=.32) or the length of the longest bleeding or spotting episode (doxycycline, placebo, P=.70) between study groups. Similarly, no significant differences in bleeding patterns existed between groups during the final 28 days. Conclusion: Doxycycline, administered once bleeding has started, does not decrease unscheduled bleeding or shorten episodes of unscheduled bleeding in continuous oral contraceptive pill users.

UR - http://www.scopus.com/inward/record.url?scp=77952969989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952969989&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3181e0119c

DO - 10.1097/AOG.0b013e3181e0119c

M3 - Article

VL - 115

SP - 1141

EP - 1149

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -